OXFORD, England, Nov. 17, 2025 /PRNewswire/ -- Accession Therapeutics Limited, a biopharmaceutical company developing next generation cancer immunotherapies, today announced it...
Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive...
Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819,...
BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Patent Extends Protection for Novel Vaccine Targeting a Cancer Projected to Strike Nearly 300,000 U.S. Women in 2026 SAN JOSE,...
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with...
First data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting SEATTLE, WASHINGTON /...
OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a...
PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company pioneering innovative cell therapies, today announced it will...
Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells...
Data presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, demonstrates the...
The world's largest tech and AI show brought groundbreaking innovations in healthcare, neurotech and life sciences to the forefront M42,...
New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation...
Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following...
Studies reveal how the Lunit SCOPE ® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery SEOUL,...
Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)King of Prussia, Pennsylvania--(Newsfile Corp. -...
Enrolling patients in ongoing randomized Phase 1b trial in MSS metastatic colorectal cancer, evaluating TTX-080 in combination with cetuximab +...
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company...
Reinvestment from existing backers underscores confidence in Elephas' predictive approach to improving immunotherapy treatment response rates MADISON, Wis., Nov. 6,...
New virtual staining solution enhances molecular diagnostics performance, preserves tissue, and accelerates turnaround times NATIONAL HARBOR, Md., Nov. 6, 2025...